Filter Your Search

Clinical Trial Search

Keyword

Principal Investigator

Condition/Disease

For Healthcare Professionals

At Henry Ford Health we serve a triple mission of Clinical Care, Research and Education. It is this triple mission that drives how we care for our patients, how we interact with referring physicians, how we work to innovate healthcare and how we train future physicians.

Learn More

Clinical Trials Search Results

MK-7339-010 - A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Principal Investigator:Clara Hwang, MD

Status: Open

Contact Phone: (313) 916-8862

Contact Email: [email protected]

MK7123-034: A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors

Principal Investigator:unassigned

Status: Open

Contact Phone: (313) 916-7453

Contact Email: [email protected]

SWOG 1802 Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Principal Investigator:Ding Wang

Status: Accepting Participants

Contact Phone: (313) 916-8862

Contact Email: [email protected]

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

Principal Investigator:Clara Hwang, MD

Status: Open

Contact Phone: (313) 916-8862

Contact Email: [email protected]

NRG GU006- A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer (BALANCE) Biomarker trial of ApaLutamide and rAdiation for recurreNt prostate CancEr

Principal Investigator:unassigned

Status: Accepting Participants

Contact Phone: 313-916-8862

Contact Email: [email protected]

PROpel D081SC00001 - A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer

Principal Investigator:Clara Hwang, MD

Status: Open

Contact Phone: (313) 916-8862

Contact Email: [email protected]

A031702-Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Principal Investigator:Haythem Y Ali, MD

Status: Accepting Participants

Contact Phone: (313) 916-8862

Contact Email: [email protected]

NRG GU008 Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer (INNOVATE)

Principal Investigator:Eleanor M Walker, MD

Status: Accepting Participants

Contact Phone: (313) 916-1784

Contact Email: [email protected]

NRG GU007-Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)

Principal Investigator:Eleanor M Walker, MD

Status: Accepting Participants

Contact Phone: 313-916-1784

Contact Email: [email protected]

Page 1 of 2 | Results 1 - 10 of 14

Browse Locations by Type Search All Locations

Frequently Searched ServicesSearch All Services

Browse Services by A-Z

Connect with Us

Resources

Research & Education

Clinical Trial Search

For Healthcare Professionals

Clinical Trials Search Results

MK7123-034: A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors

SWOG 1802 Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

NRG GU006- A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer (BALANCE) Biomarker trial of ApaLutamide and rAdiation for recurreNt prostate CancEr

PROpel D081SC00001 - A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer

A031702-Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

NRG GU008 Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer (INNOVATE)

NRG GU007-Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)

Browse Locations by Type Search All Locations

Frequently Searched ServicesSearch All Services

Browse Services by A-Z

Connect with Us

Resources

Research & Education

Clinical Trial Search

For Healthcare Professionals

Clinical Trials Search Results

Consent for Cookie Use